We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+13.46%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.15B
AUM Growth
+$28.4M
(+1.3%)
Cap. Flow
-$577M
Cap. Flow
% of AUM
-26.84%
Top 10 Holdings %
Top 10 Hldgs %
29.86%
Holding
143
New
30
Increased
17
Reduced
35
Closed
30
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RNA
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
|
+$75.8M |
| 2 |
THOR
THORATEC CORPORATION
THOR
|
+$31.1M |
| 3 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
+$30.7M |
| 4 |
Viatris
VTRS
|
+$27.4M |
| 5 |
Traws Pharma
TRAW
|
+$24.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
OPTR
OPTIMER PHARMACEUTICALS, INC. COM STK
OPTR
|
+$43.8M |
| 2 |
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
|
+$42.7M |
| 3 |
Nektar Therapeutics
NKTR
|
+$34M |
| 4 |
STJ
St Jude Medical
STJ
|
+$24M |
| 5 |
SGNT
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
|
+$23.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 52.2% |
| 2 | Technology | 1.35% |
| 3 | Financials | 1.05% |
| 4 | Consumer Discretionary | 0% |
| 5 | Energy | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CBST
1
CALL
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
| $95.3M | 4.43% |
1,500,000
| – | – |
|
|
NXTM
2
DELISTED
NxStage Medical Inc.
NXTM
| $66.2M | 3.08% |
5,027,164
+1,117,250
| +29% | +$14.7M |
|
|
ARRY
3
DELISTED
Array Biopharma Inc
ARRY
| $65.8M | 3.06% |
10,585,406
-300,000
| -3% | -$1.78M |
|
4
Pfizer
PFE
$143B
| $51.8M | 2.41% |
1,902,470
-52,700
| -3% | -$1.43M |
|
5
AstraZeneca
AZN
$262B
| $48.2M | 2.24% |
928,000
| – | – |
|
|
AUXL
6
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
| $45.3M | 2.11% |
2,488,328
-2,362,316
| -49% | -$42.7M |
|
7
AbbVie
ABBV
$450B
| $45M | 2.09% |
1,005,000
+388,000
| +63% | +$17.2M |
|
|
KERX
8
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $38.8M | 1.81% |
3,849,296
-2,015,316
| -34% | -$17.9M |
|
|
INFI
9
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $37.9M | 1.76% |
2,171,744
-183,219
| -8% | -$3.51M |
|
|
CBST
10
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
| $35.2M | 1.64% |
554,000
-141,000
| -20% | -$8.52M |
|
|
ATRS
11
DELISTED
Antares Pharma, Inc.
ATRS
| $35.1M | 1.63% |
8,653,119
-746,881
| -8% | -$3.26M |
|
12
Teva Pharmaceuticals
TEVA
$37.3B
| $33.7M | 1.57% |
892,759
-350,000
| -28% | -$13.7M |
|
|
THOR
13
DELISTED
THORATEC CORPORATION
THOR
| $33.2M | 1.55% |
+891,000
| New | +$31.1M |
|
14
Tenet Healthcare
THC
$16.8B
| $32.5M | 1.51% |
788,000
+379,880
| +93% | +$15.9M |
|
|
FRX
15
DELISTED
FOREST LABORATORIES INC
FRX
| $31.9M | 1.48% |
745,000
-200,000
| -21% | -$8.69M |
|
|
DYAX
16
DELISTED
DYAX CORPORATION
DYAX
| $30.4M | 1.41% |
4,432,625
+3,752,759
| +552% | +$17M |
|
|
17
Viatris
VTRS
$20.1B
| $29.7M | 1.38% |
+778,000
| New | +$27.4M |
|
18
Community Health Systems
CYH
$465M
| $29.5M | 1.37% |
861,203
+91,493
| +12% | +$3.24M |
|
|
AIRM
19
DELISTED
Air Methods Corp
AIRM
| $29M | 1.35% |
680,561
-188,464
| -22% | -$7.24M |
|
|
MNTA
20
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $28.9M | 1.34% |
+2,007,886
| New | +$30.7M |
|
|
AVDL
21
DELISTED
Avadel Pharmaceuticals
AVDL
| $28.4M | 1.32% |
4,333,475
| – | – |
|
|
TRNX
22
DELISTED
TORNIER N V SHARES (NLD)
TRNX
| $28.2M | 1.31% |
1,458,071
-188,247
| -11% | -$3.5M |
|
|
XOMA
23
DELISTED
Xoma
XOMA
| $27.4M | 1.27% |
304,832
+244,832
| +408% | +$22.3M |
|
|
AGN
24
CALL
DELISTED
Allergan Inc
AGN
| $27.1M | 1.26% |
300,000
| – | – |
|
25
Pacific Biosciences
PACB
$447M
| $27M | 1.25% |
4,884,368
| – | – |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q3 2013 Portfolio in Review
As of Q3 2013, Deerfield Management held 143 positions worth $2.15B, up 1.3% from $2.12B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Deerfield Management withdrew a net $577M in Q3 2013, closing 30 positions and reducing 35 holdings. Its most notable exit was OPTIMER PHARMACEUTICALS, INC. COM STK, an estimated $43.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 52% of assets, up from 51% a quarter earlier, followed by Technology and Financials.
Against the trend, Deerfield Management opened a new position in PROSENSA HLDGS N V ORD SHS (NLD) worth $21.3M.
- Deerfield Management's largest Q3 2013 buy was PROSENSA HLDGS N V ORD SHS (NLD): 3,224,524 shares worth $21.3M.
- Deerfield Management added most to Spectrum Pharmaceuticals Inc in Q3 2013, an estimated $24.3M increase.
- Deerfield Management's biggest Q3 2013 reduction was AUXILIUM PHARAMCEUTICALS INC, cutting an estimated $42.7M.
- Deerfield Management fully exited OPTIMER PHARMACEUTICALS, INC. COM STK in Q3 2013, selling an estimated $43.8M.
- Deerfield Management's ten largest holdings make up 30% of its $2.15B portfolio in Q3 2013.
- Deerfield Management opened 30 new positions and closed 30 in Q3 2013.
- Deerfield Management's portfolio value rose 1.3% quarter-over-quarter to $2.15B.
Based on Deerfield Management's 13F filing for Q3 2013, filed 14 Nov 2013.